Yolande Jacot – författare
Visar alla böcker från författaren Yolande Jacot. Handla med fri frakt och snabb leverans.
4 produkter
Methods for Risk Assessment of Transgenic Plants
IV. Biodiversity and Biotechnology
Av Richard Braun, Yolande Jacot m. fl.
E-bok, 2012
1470 kr
Lägg i varukorg
For centuries, TK has been used almost exclusively by its creators, that is, indigenous and local communities. Access to, use of and handing down of TK has been regulated by local laws, customs and tmditions. Some TK has been freely accessible by all members of an indigenous or local community and …
Methods for Risk Assessment of Transgenic Plants
III. Ecological risks and prospects of transgenic plants, where do we go from here? A dialogue between biotech industry and science
Av Vibeke Simonsen, Gosta Kjellsson m. fl.
E-bok, 2012
1427 kr
Lägg i varukorg
The Berne Symposium invited leading scientists of risk assessment research with transgenic crops on an international level in order to enhance the discussion regulators and members of the biotech industry. The goal was to determine the status quo and also to make progress in times of a first global …
Methods for Risk Assessment of Transgenic Plants
IV. Biodiversity and Biotechnology
Av Klaus Ammann, Yolande Jacot m. fl.
Häftad, 2012
1098 kr
Lägg i varukorg
For centuries, TK has been used almost exclusively by its creators, that is, indigenous and local communities. Access to, use of and handing down of TK has been regulated by local laws, customs and tmditions. Some TK has been freely accessible by all members of an indigenous or local community and …
Methods for Risk Assessment of Transgenic Plants
III. Ecological risks and prospects of transgenic plants, where do we go from here? A dialogue between biotech industry and science
Av Klaus Ammann, Yolande Jacot m. fl.
Häftad, 2013
1098 kr
Lägg i varukorg
The Berne Symposium invited leading scientists of risk assessment research with transgenic crops on an international level in order to enhance the discussion regulators and members of the biotech industry. The goal was to determine the status quo and also to make progress in times of a first global …
